CG 바카라사이트 소울카지노 reports Q1 sales of KRW 1.8 billion, a 260% increase year-on-year

[by Ji, Yong Jun] CG 바카라사이트 소울카지노, a leading player in digital genome-based novel drug development, reported a more than threefold increase in sales for Q1 2025 compared to the same period last year.

CG 바카라사이트 소울카지노 reported on May 15 that it achieved around KRW 1.8 billion (approximately USD 1.2 million) in sales and an operating loss of around KRW 3.5 billion on a standalone basis in the first quarter. This represents a 260% increase in sales compared to the same period last year (KRW 500 million) and a roughly 32% reduction in operating loss. The company characterized this progress as a first step toward comprehensive performance improvement.

CG 바카라사이트 소울카지노 indicated that sales from the newly launched genome testing service sector in April are anticipated to contribute to Q2 results, driven by strong sales of Acelex (polmacoxib) and ongoing internal cost reduction efforts.

"We are currently undergoing a turnaround through structural innovation and the establishment of new growth engines," said Lee Ho-young, CEO of CG 바카라사이트 소울카지노. "The first quarter performance was supported by existing pipeline sales serving as a bridge, and from the second quarter, the full-scale growth of our digital genome-based precision healthcare business will be reflected in market performance," he added.

On the other hand, the 바카라사이트 소울카지노 Ecosystem, encompassing CG 바카라사이트 소울카지노, is a healthcare company group dedicated to advancing data-driven personalized health management, disease management, and AI-based disease prediction. It is building a full-cycle value chain for personalized precision healthcare, encompassing data measurement, collection, analysis, integration, and commercialization, by organically linking their core competencies they each possess.